Dr. Ingegerd Hellstrom, MD, PhD
University of Washington
There is a great need to develop specific and sensitive tools for early detection of ovarian cancer because survival rates for patients are highest when tumors are detected at an early stage (I/II) as compared to low survival rates for patients with advanced stage tumors. In addition, similar tools would be useful for monitoring patients undergoing ovarian cancer treatment in order to detect and treat relapses sooner. One such diagnostic measuring tool, or assay, which has attracted much attention because it is non-invasive, quick, and relatively inexpensive involves measuring protein biomarkers released by tumor cells into blood, urine, and other bodily fluids.